SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Joint pain anatomy medical concept
Immunology and inflammation
Roivant, Pfizer’s Therapy Shows ‘Patient-Centered Benefit’ in Rare Inflammatory Condition
Brepocitinib remains “ahead of competition” in the dermatomyositis space, according to analysts at Leerink, who projected that the drug candidate could hit $2 billion in sales in 2032.
September 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative artwork strange collage of woman touch head suffer terrible tension ache.
Pain
Lexicon Backs Phase III Go Decision for Non-Opioid Pain Med With Post-Hoc Analysis
Supporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage development—despite a topline miss in March—is an “improving” regulatory environment for non-addictive options for chronic pain, according to analysts at Jefferies.
September 18, 2025
 · 
2 min read
 · 
Tristan Manalac
One Death in the HAVEN 1 Trial Complicates Roche’s Entry into the Hemophilia A Market
Mergers & acquisitions
Roche Makes Major MASH Move With $3.5B 89bio Buy
The star of the acquisition, which includes a contingent value right of $6 per share, is pegozafermin, an FGF21 analog in late-stage development for metabolic dysfunction-associated steatohepatitis.
September 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Cardiovascular disease
Deep Dive: Oral Obesity Drugs on the Cusp
In this deep dive, BioSpace explores the next big thing in obesity.
September 18, 2025
 · 
3 min read
 · 
Heather McKenzie
CDC
Republicans Ratchet Up Pressure as Monarez Levels Damning Allegations Against Kennedy
During a hearing in front of the Senate’s HELP committee, Susan Monarez addressed her controversial firing and recalled a conversation where Health Secretary Robert F. Kennedy Jr. allegedly said that “CDC employees were killing children and they don’t care.”
September 17, 2025
 · 
4 min read
 · 
Heather McKenzie
IN PARTNERSHIP WITH Pii, A JABIL COMPANY
Webinar: Bridging Formulation & Device | Integrated Supply Chain Strategies for US Pharma Manufacturing
Listen now for a high-level discussion on overcoming pharmaceutical supply chain challenges through end-to-end integration.
September 17, 2025
 · 
1 min read
 · 
BioSpace Insights
Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.
Layoffs
Innate Sheds 30% of Staff, Narrows Pipeline Focus Amid ‘Challenging Funding Environment’
Moving forward, Innate will focus on the clinical development of its antibody-drug conjugate IPH4502, the lymphoma candidate lacutamab and the AstraZeneca-partnered monalizumab.
September 17, 2025
 · 
1 min read
 · 
Tristan Manalac
Businessman tied up with red tape. concept of struggle, limitation and trap or challenge
FDA
FDA’s Ad Crackdown Targets Novo, Lilly’s Oprah Special on GLP-1s
In letters to Eli Lilly and Novo Nordisk, the FDA accused the companies of downplaying the risks of their GLP-1 weight loss drugs during a prime time special with Oprah Winfrey.
September 17, 2025
 · 
3 min read
 · 
Annalee Armstrong
Gavel inside tv isolated on orange background. 3d illustration
FDA
FDA Takes Long Overdue Baby Step Toward Regulating Compounder Drug Ads
A complex state vs. federal regulatory scheme allows drug compounders to advertise drugs without disclosing risks like a pharma company must do. Experts say it’s time for the FDA to crack down.
September 17, 2025
 · 
7 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS